Abstract:HomeCirculation: Heart FailureVol. 3, No. 4Evaluation of Toxicity for Heart Failure Therapeutics Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessResearch ArticlePDF/EPUBEvaluation of Toxicity for Heart Failure TherapeuticsStudying Effects on the QT Interval Michael G. Link, MD, Gan-Xin Yan, MD, PhD and Peter R. Kowey, MD Michael G. LinkMichael G. Link From the Main Line Heart Center and Lankenau Institute for Medical Research, Jefferson Medical College, Wynnewood, Pa. , Gan-Xin YanGan-Xin Yan From the Main Line Heart Center and Lankenau Institute for Medical Research, Jefferson Medical College, Wynnewood, Pa. and Peter R. KoweyPeter R. Kowey From the Main Line Heart Center and Lankenau Institute for Medical Research, Jefferson Medical College, Wynnewood, Pa. Originally published1 Jul 2010https://doi.org/10.1161/CIRCHEARTFAILURE.109.917781Circulation: Heart Failure. 2010;3:547–555One of the most feared complications in medicine is sudden death caused by drug-induced proarrhythmia. Accordingly, concerted efforts have been made to define a drug's proarrhythmic potential before regulatory approval. Monitoring for QT prolongation is one such method. Patients with heart failure represent a particularly high-risk population for torsade de pointes because of structural and electric remodeling that impair repolarization reserve. However, these patients are frequently excluded from clinical trials. Preclinical models simulate some of the electric remodeling of heart failure and form an important part of safety evaluations during early drug development. Clinical programs usually include a thorough QT study, which attempts to find a small mean change in QTc that serves as a surrogate for the risk of torsade de pointes. The impairment of repolarization reserve in heart failure goes beyond QT prolongation, however, and other clinical methods of measuring this propensity may be necessary to obtain a complete picture of a drug's arrhythmic potential.Heart failure (HF) is a common and serious affliction. HF is a listed diagnosis in as many as 65% to 70% of hospital admissions each year in the United States.1 The prevalence of this disease continues to increase because of to a rise in coronary artery disease and diabetes incidence, an increase in the age of the population, and a reduction in the probability of sudden cardiac death (SCD) in HF with aggressive use of implantable cardioverter-defibrillators. The net result is a larger population of patients living longer with more comorbidities, and, as a corollary, more polypharmacy. HF has been recognized as one of several clinical risk factors for drug-induced proarrythmia.2,3 Many classes of drugs have been shown to improve all-cause mortality in HF and have revolutionized both the treatment and prognosis of this condition. Although there is a need for continued development of drug treatments for HF, we must ensure that these treatments do not increase the risk for life-threatening arrhythmias.Assessing this risk accurately, however, has proven challenging. Although antiarrhythmic drugs are understood to have proarrhythmic potential, it has only recently been understood that noncardiac drugs also carry such risk. The withdrawal of terfenadine (Seldane) from the market in 1998 due to several cases of torsade de pointes (TdP) markedly heightened awareness that such drugs can be cardiotoxic. Since then, numerous noncardiac drugs have been withdrawn from the market because of a TdP risk, including prenylamine, cisapride, and sparfloxacin. In a large sample of patients treated between 1995 and 2003, the use of QT-prolonging drugs in the general population was associated with a significantly increased risk of SCD.4 In patients with coronary artery disease, the use of QT-prolonging drugs confers a higher risk of SCD, especially in patients with diabetes mellitus.5 This has led to increased oversight by regulatory bodies. Concern about proarrhythmia has become the most common reason for drug nonapproval since the turn of the century.6 The most important predictor of TdP is QT interval prolongation, and therefore TdP and drug-induced QT prolongation have become virtually synonymous.There appear to be 3 components that are necessary for the genesis of TdP: lengthening of the cardiac action potential duration (APD), early afterdepolarizations (EAD), and transmural dispersion of repolarization allowing for propagation of the EAD and reentry.7 Clinical risk factors for TdP, as described by Roden, include HF, which, in many ways, is an excellent example of how 1 or more of these requisite conditions can be met.2This article will discuss the cellular basis for repolarization abnormalities in HF, the preclinical assessment of TdP risk including in vitro and in vivo models, clinical assessments including the thorough QT study, ideas for refinement of the process, and finally, examples of emerging HF treatments and how their liabilities are being assessed.Ionic and Cellular Basis for Ventricular Repolarization Abnormalities in HFThe QT interval on the body surface represents 2 sequential ventricular electric events: ventricular depolarization (activation) that is marked by the QRS complex, and ventricular repolarization that starts with the J point and extends to the end of the T wave. Although ventricular activation time is relatively constant, ventricular repolarization is influenced by a variety of pathological conditions and drugs. It is generally accepted that ventricular repolarization time is largely determined by the repolarization of M cells, which reside in the deep subendocardium,8 and by M-cell electronic interaction with epicardial and endocardial layers.9In HF, there are several changes at the myocyte level that tend to prolong repolarization time and facilitate reentry. This electric remodeling goes hand in hand with structural remodeling. As remodeling progresses, delayed ventricular repolarization manifests as a prolonged QT on the surface ECG. The risk of all-cause mortality in HF patients has been shown to triple in the presence of QT prolongation.10,11The ionic changes that underlie ventricular repolarization abnormalities and that in turn give rise to arrhythmias in HF are complex. The most striking and consistent alteration is APD prolongation caused by the downregulation of several potassium currents responsible for repolarization. These include the inward rectifier K+ current (Ik1), the transient outward K+ current (Ito),12 the slowly activating delayed rectifier K+ current (IKs),13 and the hERG channel mediating the rapidly activating delayed rectifier current (IKr).14 Upregulation of the late sodium current (INa) also contributes importantly to QT prolongation and ventricular arrhythmias in HF.15,16The second important component is EADs. In rabbits with HF (the renal vascular occlusion model), APD is prolonged in the subendocardium, leading to QT prolongation and the development of spontaneous EADs (Figure 1).17 Similarly, in rabbits with HF after ligation of the left descending coronary artery, hypertrophied myocytes near the zone of infarction undergo electric remodeling in a fashion very similar to that in humans. When these animals are exposed to QT-prolonging drugs, there is an increase in spontaneous EADs attributable to impaired calcium handling eventuating in TdP.18 Similarly, in a study using the canine AV block HF model, TdP occurred in 3 of 12 dogs, all of which had high-amplitude EADs, compared with no TdP in EAD-negative dogs.19Download figureDownload PowerPointFigure 1. Transmural action potentials in the rabbit left ventricular hypertrophy renovascular model. A, Left ventricular hypertrophy (LVH) led to APD, along with EAD genesis in the subendocardium and endocardium. B, Graphic representation. Note that APD90 is longer at all transmural distances in the LVH model. Reprinted with permission.17In patients with left ventricular hypertrophy and cardiomyopathy, ventricular repolarization abnormalities related to dispersion of repolarization may manifest as increased beat-to-beat QT interval variability and T-wave alternans. This may be reflected on the surface ECG as a giant T-U wave occurring after long-short intervals when repolarization is maximally heterogeneous and intracellular calcium concentrations are at their highest.20 In the rabbit HF model, beat-to-beat QT interval variability and T-wave alternans are the consequence of heterogeneous beat-to-beat changes in action potential duration across the ventricular wall.21Clearly, cardiac remodeling in HF leads to ventricular repolarization changes that render the ventricle vulnerable to the development of TdP, particularly when exposed to QT-prolonging drugs. Thus, it is critical to carefully evaluate new agents in preclinical and clinical models to understand their propensity to cause TdP.Preclinical Assessment of Drug-Induced QT Liability: Implication of HFRegulatory guidelines recommend a battery of preclinical tests to assess proarrhythmic liability of all new chemical entities.The extent of QT prolongation is not the sole determinant of the TdP risk. In addition, the actual incidence of TdP for noncardiac drugs is very low, between 1 in 10 000 to 1 in 100 000 patients. Terfenadine, removed from the US market in 1998, caused 1 episode of TdP for every 28 500 prescriptions.22 Thus, only a small subset of patients are prone to develop TdP, and these patients may do so after years of exposure to the culprit drug.2,23 Although there may be several pathological factors that reduce ventricular repolarization reserve and predispose humans to TdP, HF is clearly one of the most important.17,24Drugs that might be used in HF patients therefore undergo careful scrutiny. Several models that mimic reduced ventricular repolarization reserve seen in HF have been developed for this purpose.18,25 Several strategies have been adopted in drug development to understand proarrhythmic potential. An early test is assessing blockade of hERG, the ionic channel targeted by most QT prolonging agents. This includes measuring relative potency, which is the concentration at which at least 50% of the ion channel is inhibited. It is also important to understand the effects of a new drug on assorted ion channels or receptors that blunt or accentuate the drug's proarrhythmic potential. Finally, these models can help to design a drug with preferential effects on atrial repolarization currents, particularly important if the indication sought is atrial fibrillation.Few of these models have been properly validated and therefore extrapolations to the clinical situation are hazardous. Regulators, though considering the data generated by these experiments, are likely to prefer clinical data for decision-making purposes. A major concern is that the effort to increase the sensitivity of preclinical tests using HF animal models may sacrifice the specificity of the tests, increasing the chance of false-positive outcomes.We have recently developed an isolated arterially perfused rabbit ventricular wedge preparation that has been validated to be highly sensitive and specific with regard to TdP prediction.26,27 Excellent predictive accuracy has been achieved in part by selecting an appropriate species and experimental preparation. The female rabbit left ventricle has a small IKs, making it particularly sensitive to QT-prolonging agents.13 It bears a close resemblance to humans, particularly HF patients, with a reduced repolarization reserve.28,29 This preparation also has a large ratio of QT signal over experimental noise. As shown in Figure 2, the response of the isolated arterially perfused rabbit ventricular wedge preparation is magnified, allowing discrimination of drugs with no QT effect from those with a weak effect on repolarization.30Download figureDownload PowerPointFigure 2. A, Arterially perfused rabbit left ventricular wedge preparation demonstrating prolongation of the QT interval, APD, and transmural gradient when exposed to representative drugs. B, Effect on the QT interval by a panel of known QT-prolonging drugs in increasing concentrations. Reprinted with permission from Elsevier.30Clinical Assessment of Drug-Induced QT Liability: The Thorough QT StudyThe first regulatory schema for evaluating the effects of new drugs on repolarization was presented in a European Society of Cardiology (ESC) policy conference in 2000 (Figure 3).31 The preclinical assessment of QT liability was to be followed by a number of clinical studies. The goal of the preclinical assessment was to identify compounds in a "worst case scenario," for example, in HF patients using suprapharmacologic doses. Clinical phase I trials were to be performed in healthy volunteers including women who are at increased risk of TdP. Doses would be escalated with measurements of parent drug and metabolites at peak and trough, after steady-state levels of all active compounds (parent and metabolites) had been achieved. ECGs were to be obtained at baseline, at steady state, and following drug withdrawal. The ESC recommended manual QT measurements including comments on changes in T-wave morphology and U waves. The QT was to be measured in all leads for 3 to 5 beats and to be corrected for heart rate with nonlinear regression formulae including confidence intervals. QT dispersion measurement was not recommended. If the drug were judged safe in phase I and early phase II trials, at-risk groups would be enrolled, including HF patients, especially if the drug were to be used in these groups.Download figureDownload PowerPointFigure 3. ESC-proposed algorithm for evaluating QT effects of drugs in development. Reprinted with permission from.31The International Conference on Harmonization document E14 reinforced these guidelines and established the industry standard for premarket QT assessment.32 These guidelines recommend performing a thorough QT/QTc (TQT) study early in development. This study is required in the United States regardless of the outcomes of preclinical testing but may be waived in Europe if preclinical studies are negative.33 Such a study is intended to be performed in healthy volunteers. Marked baseline QT prolongation, presence of risk factors for TdP (including heart failure), and concomitant use of medications known to prolong the QT interval are exclusion criteria. The threshold for regulatory concern is set at a maximal time-matched mean prolongation of QTc of 5 ms, which is derived almost exclusively from the data for terfenadine.34 These studies should be randomized, blinded, and placebo- and positive-controlled, with either a parallel or crossover design (Figure 4). Crossover studies have the advantages of requiring fewer subjects and individual placebo subtraction, whereas parallel studies are required for the study of drugs with longer half-lives.35 The positive control for the TQT study is an agent known to prolong the mean QTc by at least 5 ms, usually moxifloxacin.Download figureDownload PowerPointFigure 4. Schematic of representative design of thorough QT study. The parallel design (A) is used primarily for drugs with long half-lives, active metabolites, or tachyphylaxis at high doses, but the preferred method is the crossover (B). The doses used as well as the magnitude of dose escalation are determined by Phase I single ascending dose or multiple ascending dose studies. Often, thorough QT studies use only a single supratherapeutic dose arm. Statistical power increases with the number of sessions performed, but there is no fixed requirement.Currently the QT interval is analyzed using a semiautomated technique in which each interval is examined by a technician before a physician overread. Automated reading has obvious advantages in facilitating the process and reducing costs. Several systems for computerized QT analysis are in development and are undergoing proper validation.36,37Dose selection is a key factor in the success of a TQT study. For drugs that are extensively metabolized, such as through the cytochrome P450 system (such as terfenadine), and particularly if the metabolite is electrophysiologically active, it may be necessary to study ECG effects under conditions of maximum inhibition or with doses that permit a replication of the maximum effect of parent and metabolite, even in patients who are organ-impaired.The definition of a negative TQT study is one in which the single-sided 95% confidence interval for the largest time-matched placebo-subtracted mean effect of the drug on the QTc interval excludes 10 ms. There are 2 possible interpretations of "largest time-matched mean": either largest change from baseline or worst of all time points. The latter is more likely to be biased toward a positive result; therefore, the largest change from baseline is most often used.There are no specific recommendations about which QT correction formula to use, although an individualized correction is most frequently used. ECGs should be measured by designated skilled readers at a centralized ECG laboratory. The interreader and intrareader variability should be established. U waves are to be excluded from the QT interval measurement. Significant end points include clinical adverse events such as syncope, an absolute QTc prolongation >500 ms, and changes from the baseline of >60 ms. Genotyping for subclinical LQTS when marked QT prolongation occurs is recommended though most often unrevealing.A negative thorough QT study obviates intensive monitoring during subsequent clinical development because drugs causing less than 5-ms changes in mean QTc are unlikely to cause TdP. Customary ECG monitoring, such as obtaining a single ECG at the time of dosing or only if an adverse event occurs, is the rule. Given the high sensitivity of TQT studies, it does not seem reasonable that minor ECG changes observed after a negative TQT should in and of themselves be grounds for subsequent denial of drug approval. Such changes might be indicative of a patient-specific or disease-specific effect, however, which could necessitate further study. A positive study necessitates more intensive safety monitoring, and testing of patients with additional risk factors for TdP, including those with heart failure.Limitations of the TQT and Future Directions for Proarrhythmic Risk Assessment in HF PatientsThe results of a thorough QT study can be difficult to reproduce and are not easily applicable to the HF population. Detecting a difference of 10 ms or less on a standard 12-lead ECG is challenging even for experienced readers. Neither the ESC nor the International Conference on Harmonization has recommended computerized readings, although there are new technologies in development that might make that practical.The finding of an increased mean QT prolongation implies either potentially significant prolongation in many subjects, or a wide variation in prolongation with grossly unequal distribution of risk. Therefore, a categorical analysis is important to determine how risk is distributed and for what reason. Unfortunately, it is statistically difficult to determine a 95% confidence interval for time-matched means. Most commonly, intersection-union tests are used, but these tests tend to have lower power than TQT studies and this may bias toward a positive test result. Also, the statistical assumptions underlying intersection-union tests may be invalid in an HF population.38As originally stated by the ESC, drugs that may be used in HF must be assessed for their proarrhythmic risk in a HF population. Additionally, proper correction of the QT is vital when the drug being tested affects autonomic tone, as many HF drugs do. Typical correction formulas tend overcorrect at higher heart rates, leading to a falsely prolonged QTc.33,39 This was demonstrated in the TQT results for vardenafil and alfuzosin. Both drugs had borderline-positive TQT when the Fridericia correction formula was used but negative results with individualized heart rate correction.40,41 This problem was also evident in the case of a new gadolinium contrast agent used for cardiac MRI, gadobutrol, which had a minimally positive thorough QT study with conventional correction but a negative study when the QT was corrected with individualized QT/R-R hysteresis.42 Also, changes in autonomic tone may be more proarrhythmic in HF patients compared with healthy volunteers. Electric remodeling leads to an increase in steepness of APD restitution curves during increased sympathetic stimulation, which in turn leads to dynamic wave instability, further loss of repolarization reserve, and therefore arrhythmic risk.43 This underscores the need for proper, reproducible QT correction.In attempting to clinically establish the proarrhythmic potential of a new drug in HF patients, it would be useful to be able to assess electric stability noninvasively. The QT interval, as we have discussed, is an important parameter, particularly when markedly prolonged. The QT/R-R slope, peak QTc, number of beats with QTc >500 ms, and variance about the mean may add predictive power.44 Other methods include heart rate variability, late potentials on signal-averaged ECG, QT dispersion, T-wave alternans, time to inscribe the second half of the T wave (Tpeak-Tend), and beat-to-beat variability of repolarization.45,46,47,48,49,50Although these tests have the potential to provide a more comprehensive assessment of repolarization reserve, validation is essential. A common failing of currently existing noninvasive assays of electric stability is high specificity for predicting fatal arrhythmias but low sensitivity. Conversely, preclinical models and TQT studies tend to be more sensitive at the expense of specificity. Therefore, a potential future approach for new drugs developed for HF patients might be to follow a preclinical study with a focused clinical analysis of the drug's total effect on repolarization in HF patients. This would not necessarily obviate the need for a TQT study but might provide added assurance of safety before embarking on costly pivotal clinical trials.HF Drugs in DevelopmentThere are several promising therapies for HF51 currently undergoing the development process, including TQT studies. Examples are presented in the Table.52–77 These therapies attempt to achieve benefit in HF including fluid reduction and enhanced contractility, using novel mechanisms that could reduce the tendencies to proarrhythmia. Because these drugs are in early stages of development, most of the current data come from animal models. The preclinical data are generally favorable with regard to their electrophysiological effects.78,79Table. Summary of Details Regarding Selected HF Therapeutics in Development and Their Effects on the QT IntervalName of DrugClassMechanism of ActionTQT ResultsNotesSitaxsentanEndothelin ETA antagonistReduces pulmonary vasoconstriction, theoretical improvement in diastolic dysfunction.52Negative TQT.53Approved for pulmonary arterial hypertension in Canada.53Increases treadmill time on Naughton protocol for patients with HF with preserved ejection fraction. 52Istaroxime (PST-2744)Luso-inotropeInhibits cardiac Na+/K+ ATPase to increase calcium availability and stimulates SERCA 2a to promote reuptake of calcium for relaxation.54Shortens QT.55Currently in phase III clinical trials.Omecantiv mecarbil (CK-1827452)InotropeCalcium-independent inotrope, direct activator of myosin.56No clinical data.Prolongs ejection time57 without increasing myocardial O2 demand or dp/dt.58Levosimendancalcium sensitizerBinds to calcium-bound troponin C, stabilizing it and increasing half-life. Also vasodilates by opening ATP-sensitive calcium channels.59Mild QTc prolongation, no proarrhythmia.60Possible survival benefit vs conventional inotropes, 62,63although not borne out in larger trials.64Increases mean APD50 by 9 to 17 ms and mean APD90 by 5 to 15 ms in healthy volunteers.61More brain natriuretic peptide lowering than dobutamine.65Improves weaning from bridge-to-recovery ventricular assist device after cardiotomy.66Ularitide (ANP 95–126)Human urodilatin (ANP family) analog67Increases diuresis via inhibition of cGMP in distal tubule and collecting duct.No TQT performed (May G, MD, unpublished data, 2009).Safety demonstrated in decompensated HF patients.68Inhibits remodeling after infarction, 69possible synergy with PDE-5 inhibitors.70Lixivaptan (OPC-21268)Oral V2 vasopressin antagonist71Blocks V2 receptors in collecting duct, enhancing free water clearance.72Completed in October 2008, results pending.73Related drugs conivaptan74 and tolvaptan75 both had negative TQT.Naxifylline (BG9719, CVT-124)Adenosine A1 antagonistEnhances diuresis by dilating renal afferent arterioles and inhibiting sodium reabsorption in the proximal and distal tubules.76No published data.Natriuresis equivalent to furosemide but without reduction in glomerular filtration rate.77The clinical data available for these drugs have been promising. Sitaxsentan (Thelin) had a negative TQT study and is currently approved in Canada for the treatment of pulmonary arterial hypertension.53 This drug may eventually be used primarily in patients with heart failure with preserved ejection fraction.54 Istaroxime underwent a TQT study that demonstrated shortening of the QT interval not associated with ventricular ectopy, ventricular fibrillation, or untoward hemodynamic effects.54 Omecantiv mecarbil (CK-1827452) also shortened the QT interval in phase I trials56 and was subsequently shown to be safe in patients with ischemic cardiomyopathy in phase II trials.80 Levosimendan slightly increased QTc, with a modest increases in APD50 and APD90 in healthy volunteers and a small increase in nonsustained ventricular tachycardia in HF patients.61,81 Its overall proarrhythmic risk is likely to be low but must be defined.ConclusionPreservation of safety is the prime directive in the use of all medications. As our patients age, the number of comorbidities increases and polypharmacy becomes more common, medication toxicity will become more commonplace. There is no more serious adverse drug event than death. Nonetheless, while preserving drug safety, we should not lose sight of the importance of novel, therapies to improve patients' symptoms and quality of life. A proper evaluation of the proarrhythmic potential of new therapeutics, in particular their effects on the QT interval, is especially critical in the HF population. The mechanism of TdP has been elegantly described, but it remains hard to predict. Because HF is uniquely associated with impaired repolarization reserve, all new therapeutics targeting heart failure patients require careful testing. Although we have several promising testing modalities for predicting the risk of proarrhythmia, each must be properly validated. The availability of better safety testing will enhance the development of HF drugs and ultimately lead to better patient outcomes.Sources of FundingThis work was supported by the W. W. Smith Charitable Trust (Dr Kowey), the Sharpe-Strumia Research Foundation (Dr Yan), and the Albert M. Greenfield Foundation (Drs Kowey and Yan).DisclosuresDr Kowey is a consultant for Forest Pharmaceuticals, Astra-Zeneca, GlaxoSmithKline, Johnson and Johnson, Medtronic, and New Cardio and has equity interest in Cardionet.FootnotesCorrespondence to Peter R. Kowey, MD, Main Line Health Heart Center, 100 Lancaster Ave, MOBE 558, Wynnewood, PA 19096. E-mail [email protected]orgReferences1. Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the US, 1979 to 2004. J Am Coll Cardiol.2008; 52:428–434.CrossrefMedlineGoogle Scholar2. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med.2004; 350:1013–1022.CrossrefMedlineGoogle Scholar3. Letsas KP, Efremidis M, Kounas SP, Pappas LK, Gavrielatos G, Alexanian IP, Dimopoulos NP, Filippatos GS, Sideris A, Kardaras F. Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors. Clin Res Cardiol.2009; 98:208–212.CrossrefMedlineGoogle Scholar4. Straus SM, Sturkenboom MC, Bleumink GS, Dieleman JP, van der LJ, de Graeff PA, Kingma JH, Stricker BH. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J.2005; 26:2007–2012.CrossrefMedlineGoogle Scholar5. Chugh SS, Reinier K, Singh T, Uy-Evanado A, Socoteanu C, Peters D, Mariani R, Gunson K, Jui J. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study. Circulation.2009; 119:663–670.LinkGoogle Scholar6. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf.2001; 24:323–351.CrossrefMedlineGoogle Scholar7. Yan GX, Wu Y, Liu T, Wang J, Marinchak RA, Kowey PR. Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome: direct evidence from intracellular recordings in the intact left ventricular wall. Circulation.2001; 103:2851–2856.LinkGoogle Scholar8. Yan GX, Shimizu W, Antzelevitch C. Characteristics and distribution of M cells in arterially perfused canine left ventricular wedge preparations. Circulation.1998; 98:1921–1927.LinkGoogle Scholar9. Yan GX, Martin J. Electrocardiographic T wave: a symbol of transmural dispersion of repolarization in the ventricles. J Cardiovasc Electrophysiol.2003; 14:639–640.CrossrefMedlineGoogle Scholar10. Kolo PM, Opadijo OG, Omotoso AB, Balogun MO, Araoye MA, Katibi IA. Prevalence of QTc prolongation in adult Nigerians with chronic heart failure. West Afr J Med.2008; 27:69–73.MedlineGoogle Scholar11. Vrtovec B, Delgado R, Zewail A, Thomas CD,

Abstract:HomeCirculation: Arrhythmia and ElectrophysiologyVol. 2, No. 1Is there a significant transmural gradient in repolarization time in the intact heart? Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessResearch ArticlePDF/EPUBIs there a significant transmural gradient in repolarization time in the intact heart?Cellular Basis of the T Wave: A Century of Controversy Chinmay Patel, James F. Burke, Harsh Patel, Prasad Gupta, Peter R. Kowey, Charles Antzelevitch and Gan-Xin Yan Chinmay PatelChinmay Patel From the Main Line Health Heart Center, Lankenau Hospital and Lankenau Institute for Medical Research (C.P., J.F.B., H.P., P.G., P.R.K., G.-X.Y.), Wynnewood, Pa; Jefferson Medical College (J.F.B., P.R.K., G.-X.Y.), Thomas Jefferson University, Philadelphia, Pa; Masonic Medical Research Laboratory (C.A.), Utica, NY; and Tong-Ji Hospital (G.-X.Y.), Tong-Ji Medical College, Huazhong University of Science and Technology, Wuhan, China. Search for more papers by this author , James F. BurkeJames F. Burke From the Main Line Health Heart Center, Lankenau Hospital and Lankenau Institute for Medical Research (C.P., J.F.B., H.P., P.G., P.R.K., G.-X.Y.), Wynnewood, Pa; Jefferson Medical College (J.F.B., P.R.K., G.-X.Y.), Thomas Jefferson University, Philadelphia, Pa; Masonic Medical Research Laboratory (C.A.), Utica, NY; and Tong-Ji Hospital (G.-X.Y.), Tong-Ji Medical College, Huazhong University of Science and Technology, Wuhan, China. Search for more papers by this author , Harsh PatelHarsh Patel From the Main Line Health Heart Center, Lankenau Hospital and Lankenau Institute for Medical Research (C.P., J.F.B., H.P., P.G., P.R.K., G.-X.Y.), Wynnewood, Pa; Jefferson Medical College (J.F.B., P.R.K., G.-X.Y.), Thomas Jefferson University, Philadelphia, Pa; Masonic Medical Research Laboratory (C.A.), Utica, NY; and Tong-Ji Hospital (G.-X.Y.), Tong-Ji Medical College, Huazhong University of Science and Technology, Wuhan, China. Search for more papers by this author , Prasad GuptaPrasad Gupta From the Main Line Health Heart Center, Lankenau Hospital and Lankenau Institute for Medical Research (C.P., J.F.B., H.P., P.G., P.R.K., G.-X.Y.), Wynnewood, Pa; Jefferson Medical College (J.F.B., P.R.K., G.-X.Y.), Thomas Jefferson University, Philadelphia, Pa; Masonic Medical Research Laboratory (C.A.), Utica, NY; and Tong-Ji Hospital (G.-X.Y.), Tong-Ji Medical College, Huazhong University of Science and Technology, Wuhan, China. Search for more papers by this author , Peter R. KoweyPeter R. Kowey From the Main Line Health Heart Center, Lankenau Hospital and Lankenau Institute for Medical Research (C.P., J.F.B., H.P., P.G., P.R.K., G.-X.Y.), Wynnewood, Pa; Jefferson Medical College (J.F.B., P.R.K., G.-X.Y.), Thomas Jefferson University, Philadelphia, Pa; Masonic Medical Research Laboratory (C.A.), Utica, NY; and Tong-Ji Hospital (G.-X.Y.), Tong-Ji Medical College, Huazhong University of Science and Technology, Wuhan, China. Search for more papers by this author , Charles AntzelevitchCharles Antzelevitch From the Main Line Health Heart Center, Lankenau Hospital and Lankenau Institute for Medical Research (C.P., J.F.B., H.P., P.G., P.R.K., G.-X.Y.), Wynnewood, Pa; Jefferson Medical College (J.F.B., P.R.K., G.-X.Y.), Thomas Jefferson University, Philadelphia, Pa; Masonic Medical Research Laboratory (C.A.), Utica, NY; and Tong-Ji Hospital (G.-X.Y.), Tong-Ji Medical College, Huazhong University of Science and Technology, Wuhan, China. Search for more papers by this author and Gan-Xin YanGan-Xin Yan From the Main Line Health Heart Center, Lankenau Hospital and Lankenau Institute for Medical Research (C.P., J.F.B., H.P., P.G., P.R.K., G.-X.Y.), Wynnewood, Pa; Jefferson Medical College (J.F.B., P.R.K., G.-X.Y.), Thomas Jefferson University, Philadelphia, Pa; Masonic Medical Research Laboratory (C.A.), Utica, NY; and Tong-Ji Hospital (G.-X.Y.), Tong-Ji Medical College, Huazhong University of Science and Technology, Wuhan, China. Search for more papers by this author Originally published1 Feb 2009https://doi.org/10.1161/CIRCEP.108.791830Circulation: Arrhythmia and Electrophysiology. 2009;2:80–88The ECG is one of the oldest and most versatile noninvasive cardiac diagnostic tests. It has remained in use essentially in its original form despite dramatic advances in cardiac electrophysiology. In May 1887, Augustus Desiré Waller recorded the first human Electrogram using a primitive instrument called a Libbmann capillary electrometer. It had 2 deflections corresponding to ventricular depolarization and repolarization.1 In 1903, Willem Einthoven invented the String Galvanometer—a more sophisticated voltage recording instrument and recorded an Elektrokardiogramm with 5 deflections that he named PQRST.2Response by Opthof et al p 80Since its initial invention, the body surface ECG has become a commonly used and extremely valuable test for the diagnosis of a variety of cardiac conditions. Despite a century of prolific use and intensive investigation, the cellular basis of ECG waveforms, particularly the T wave, remains a matter of debate.Anecdote of the T waveThe saga of the T wave began in 1856, when 2 German physiologists Kölliker and Müller attempted to explore the electric activity of the heart using frog sciatic nerve attached to gastroenemius muscle as a voltage recording instrument and observed 2 contractions (see review by Noble and Cohen3). In retrospect, the second “contraction” probably reflected a voltage gradient related to the T wave of Einthoven. In 1883, Burdon-Sanderson and Page4 were the first to demonstrate that in the frog’s heart, the wave of excitation spreads from the base to the apex of the ventricle. The record was diphasic, with the first positive (R) wave followed by a negative (T) wave. They also demonstrated that the T wave corresponds to repolarization of the ventricle. Similar series of experiments by Bayliss and Starling in 18925 in the canine heart showed that the T waves are usually upright in mammals. This was followed by Mines6 on frog’s heart using Einthoven’s String Galvanometer in 1913. Mines stated that the T wave is an electric expression of asymmetrical passing off of excitation (repolarization) in different parts of the ventricles and that the polarity of the T wave can be predicted by changing the duration of the action potential in a controlled manner. In 1931, Wilson et al7 put forward the hypothesis that the concordance of the T wave with the R wave on the surface ECG can be explained by assuming that the depolarization and the repolarization waves must travel in opposite directions at least in some parts of the ventricle. The biophysical principle behind this hypothesis requires that the cells that activate first have to repolarize last to produce a T wave of the same polarity of that of the R wave. In other words, the action potential duration (APD) in the cells that are excited first should be significantly longer than the cells that are excited last.In an attempt to explain the positive polarity of the T wave in mammals, Noble and coworkers8 in 1976 recorded action potentials from tissue slices dissected from the “base” and the “apex” of the sheep ventricle and showed that at steady state, APD is longer at the “base” as compared with the “apex.” They concluded that such a difference could account for a positive polarity of the T wave in mammals. This series of experiments laid down the foundation of the controversial hypothesis that apico-basal difference in the time course of repolarization underlies the genesis of a positive T wave. The theory of apico-basal dispersion of repolarization as a basis of the electrocardiographic T wave dominated the medical literatures until the 1990s when the discovery of M cells9,10 and the development of the left ventricular wedge technique11–14 suggested that the transmural dispersion of repolarization may contribute importantly to the genesis of the T wave.Second Look at HistoryNoble’s work is frequently cited as supporting the role of an apico-basal voltage gradient in the genesis of the T wave.8 It is important to note that the tissue slices used for recording the action potential were dissected from the endocardial surface of the base and the epicardial surface of the apex of the sheep’s ventricle. In Noble’s own words, “Small pieces of tissue were dissected from 2 regions of sheep left ventricle (LV)—the upper part (base) of the interventricular septum and the epicardial surface of the apex. The former is endocardial and the latter is epicardial.” In other words, the tissue slices from the “base” represented the endocardium and from the “apex” represented the epicardium. Hence, the voltage gradient seen in Noble’s study though frequently cited as apico-basal could very well have been transmural (between endocardium and epicardium).According to the biophysical principle of impulse propagation, a positive T wave in sheep would require earlier activation of basal cells (longer APD) as compared with apex (shorter APD). However, mapping studies in mammals have shown that depolarization in the ventricles spreads from the apex to the base, and the base is usually the last area to be activated.15–17 Earlier activation of the apical cells combined with a late activation of the basal cells would lead to a negative T wave, which is not the usual case in mammals. Recently, Noble18 himself has acknowledged the presence of transmural repolarization gradient and its possible role in the inscription of the T wave.Transmural Voltage Gradient: Unrecognized Historical EvidenceAlthough it was not the predominant hypothesis before 1990s, multiple studies had suggested the presence of a transmural voltage gradient, and its contribution to the genesis of the T wave. In 1959, Reynolds and Vander Ark19 demonstrated that in the canine heart, earlier repolarization of epicardium as compared with endocardium was associated with a positive T wave and vice versa. In 1972 Burgess et al20 showed that the ventricular functional refractory periods are longer on the endocardium than epicardium and apex as compared with the base. Using the glass microelectrode technique, Solberg et al21 in 1974 recorded transmembrane action potentials from tissue slices obtained from the canine papillary muscle. They demonstrated a transmural gradient of repolarization with the subendocardial cells having the longest duration of action potential followed by the endocardial and epicardial cells. Similar evidence that earlier repolarization occurs in the canine epicardium was obtained by Spach and Barr15 and Abildskov22 in 1975.In an elegant experimental model of an open chest canine heart, in 1984, Higuchi and Nakaya et al23 recorded monophasic action potentials from the endocardial and the epicardial surface of the LV with a simultaneous recording of an epicardial-unipolar ECG in close proximity. They found a high degree of correlation between the transmural APD gradient and the polarity of T wave. In their experiments, warming the epicardial surface by dropping warm physiological saline solution led to abbreviation of epicardial APD with a resultant increase in transmural APD gradient, which manifested itself as an increase in the amplitude of the upright T wave on the ECG. In contrast, cooling of the epicardial surface led to prolongation of the epicardial APD with a reversal of transmural repolarization gradient, manifested as negative T waves.This classic work was followed by a study by Franz et al24 in the human heart. He recorded monophasic action potential from the endocardial and epicardial surfaces of the human heart and showed that epicardial repolarization occurs earlier than the endocardium leading to a transmural repolarization gradient.M Cell and the Left Ventricular Wedge PreparationThe discovery of the M cell (Masonic, Midmyocardial, Moe cell)9,11 has significantly advanced our understanding of the transmural voltage gradient. An increasing number of studies have shown that the ventricular myocardium is not a homogeneous structure, but it is comprised of 3 distinct cell types, ie, epicardial, subendocardial and endocardial cells, with clearly distinct electrophysiological and pharmacological properties. The M cells are located in deep subendocardium of the canine LV.9,10 The hallmark of M cells is the ability of its action potential to prolong more than that of the epicardium or endocardium in response to slowing of the rate or in response to agents that prolong APD.The development of the canine and rabbit left ventricular wedge models has greatly advanced our understanding the role of electric heterogeneity in the genesis of the repolarization waves of the ECG.12,13 This experimental preparation provides us with the unique ability to record transmembrane action potentials from 3 different myocardial cell types simultaneously together with a pseudo-ECG. Because the pseudo-ECG is recorded by placing 2 electrodes in the Tyrode’s solution (ie, a homogenous volume conductor) bathing the wedge preparation 1 to 1.5 cm from the epicardial and endocardial surfaces, the electric field of the preparation as a whole is measured. We use the pseudo-ECG to distinguish it from the body surface ECG, although both recordings are principally similar. The simultaneous recordings of transmembrane action potentials and the pseudo-ECG provides us with ability to correlate changes in APD with those in ECG morphology. Using the wedge preparation, we have demonstrated that differences in the time course of repolarization of the 3 predominant myocardial cell types contribute to electrocardiographic inscription of the T wave in pseudo-ECG.13 As shown in Figure 1, the different time course of repolarization of phases 2 and 3 of the 3 principle myocardial cell types gives rise to opposing voltage gradients on either side of the subendocardial M cells, leading to the inscription of the T wave. In the case of an upright T wave, the epicardial cells repolarize earliest and the M cells repolarize last. Final repolarization of the epicardial cells coincides with the peak of the T wave and final repolarization of the M cells coincides with the end of the T wave.25,26 Thus, the M cell APD approximates the QT interval and the epicardial APD approximates the QTpeak interval. The interval from the peak of T wave to the end of T wave (Tp-e) correlates closely with transmural dispersion of repolarization (TDR). Also, the polarity of the T wave can be changed by changing the APD in a controlled manner. Download figureDownload PowerPointFigure 1. A, The cellular basis of the T wave in the canine left ventricular wedge preparation. Simultaneous recordings of action potential with of 3 different cell type with a pseudo-ECG are shown. Note that the opposing voltage gradient on either side of the M region leads to inscription of the T wave. The peak of the T wave coincides with the end of repolarization of the epicardial cell and the end of the T wave coincides with the end of repolarization of the M cells. B, The cellular basis of the T wave in the rabbit left ventricular wedge. In the rabbit, the entire endocardium has the same electrophysiological properties as M cells. Therefore, the end of the T wave coincides with the end of repolarization of the endocardium in the rabbit. Epicardial pacing leads to earlier activation of epicardial cells with shorter APD and delays the activation of endocardial cells with a longer APD, leading to an increase in QT and Tp-e interval. Epi, Epicardium; Endo, Endocardium; AP, action potential. Modified and reproduced with permission from Circulation. 1998;98:1928–1936.Is there an Apico-Basal Voltage Gradient in the LV?It has been argued that the canine left ventricular wedge is too small a sample and does not reflect what might happen in an intact heart.27 This prompted us to develop an experimental model where we use the intact rabbit LV instead of a wedge. In this model, we tested the relative role of the transmural versus the apico-basal voltage gradient in the genesis of the T wave. We elected to use the rabbit LV instead of the dog for several reasons. First, as shown in Figure 2A, the isolated rabbit LV is perfused by cannulating the left main coronary artery that allows us to use the complete left ventricular tissue in the experiment and it ensures that the preparation is well perfused. Because it includes the whole ventricle it allows us to record the transmural and the apico-basal voltage gradient simultaneously. Secondly, cells with electric resemblance to the M cells are located in the endocardium of the rabbit LV,28,29 so that it is technically easier to simultaneously record action potentials from the endocardium and epicardium. The action potential recordings obtained from intact epicardial and endocardial surface eliminates the possibility of injury and uncoupling due to dissection. Some have proposed that transmural dispersion of repolarization seen in the small canine wedge preparation may be related to injury and uncoupling of the cells because the action potential is recorded from a transected subendocardial surface.30,31 Realistically the cut surface constitutes only an extremely small fraction of the entire wedge preparation that should have little influence on the pseudo-ECG. In any case, the arterially-perfused rabbit LV is devoid of such a confounding factor. Download figureDownload PowerPointFigure 2. A, Schematic presentation of the arterially perfused rabbit LV. LM, left main coronary artery; LAD, left anterior descending coronary artery; LCD, left circumflex coronary artery. B, Schematic presentation of simultaneous recording of 4 sets of action potentials: apical epicardium, apical endocardium, basal epicardium and basal endocardium together with 2 pseudo-ECGs: transmural and apico-basal. Epi, epicardium; Endo, endocardium.The arterially perfused rabbit LV was prepared in a similar way as the rabbit left ventricular wedge.28,32–34 To accomplish this, as shown in Figure 2B, we recorded the endocardial and the epicardial transmembrane action potentials simultaneously from the apical and the basal areas of the rabbit LV. Two pseudo-ECGs were recorded: one recorded transmurally and another across the apico-basal axis of the left ventricular wall. It is important again to emphasize that the pseudo-ECGs were recorded in the volume conductor in which the electrodes were placed at least 2 cm from the epicardial and endocardial surfaces, or from the apex and base of the isolated LV. After control recording at a basic cycle length of 1000 ms, 0.1 μmol/L cisapride at was infused to determine if it has any preferential effects on epicardial/endocardial or apical/basal cell action potential.Representative recordings from these experiments are shown in Figure 3A. Under control conditions, the APD of apical cells (both endocardial and epicardial surfaces) was slightly longer than the APD of the respective basal cells; however, the difference was not statistically significant. On the other hand, both at the apical and the basal recording sites, the APD of the endocardial cells were consistently longer than the epicardial cells and the results were statistically significant. This difference in the time course of repolarization of the epicardial and endocardial cells, ie, the transmural dispersion of repolarization, caused the inscription of the T wave in the pseudo-ECG recorded across the transmural axis. In both apical and basal recording sites, the peak of the T wave was coincident with the end of repolarization of the epicardium and the end of T wave was coincident with the end of repolarization of the endocardium. In contrast, the pseudo-ECG recorded along the apico-basal axis had T waves that were either flat or negative. Download figureDownload PowerPointFigure 3. A, A representative recording from the rabbit LV showing well-defined T waves in pseudo-ECGs recorded across the transmural axis under control conditions and after infusion of cisapride. Note that the pseudo-ECG recorded across the apico-basal axis fails to reveal any T waves, and there is no correlation between changes in APD and ECG morphology. B, Composite data showing similar findings in 4 similar experiments. Note that APD was slightly longer at the apex as compared with the base; however, the difference is not as pronounced as seen between the endocardium and the epicardium. AP, action potential; Epi, epicardium; Endo, endocardium; APD90, APD at 90% repolarization. **P<0.05 compared between endocardium vs epicardium, ##P<0.05 compared between apex vs base.After infusion of the IKr blocker cisapride, the QT interval prolonged with a preferential prolongation of APD of the endocardial cells as compared with the epicardial cells across the entire LV, leading to an increase in TDR and a corresponding increase in the duration of descending limb of the T wave, ie, the Tp-e interval. Cisapride increased the APD of the apical cells slightly more than the basal cells; however the observed difference was not statistically significant. Once again, the apico-basal pseudo-ECG showed nonspecific T wave morphologies and we were unable to identify any corelation between the morphological changes in action potential and the pseudo-ECG. Findings were reproduced in 4 similar experiments. Composite data are shown in Figure 3B.The canine left ventricular wedge spans 5 cm of the LV across the apico-basal axis. A decade of experience with this preparation confirmed that there is no significant dispersion of repolarization across the apico-basal axis in such a small segment of LV.13 Does this hold true in an entire canine LV? This issue was elegantly addressed in recent work by Rosenbaum and coworkers35 in canine hearts using optical mapping technique. In this study investigating the physiological basis of T wave memory, 3 wedge preparations were used from anterior, lateral, and posterior surface of canine LV, respectively. Action potentials were recorded with optical mapping technique from all 3 wedge preparations. The dispersion of repolarization was calculated across the transmural axis of each wedge (ie, TDR) and also between 2 LV wedges (ie, segmental dispersion of repolarization). The transmural pseudo-ECG was calculated by subtracting the action potentials from epicardial cells and M cells. The segmental ECG was calculated by subtracting action potentials of M cells recorded from 2 different LV wedges/segments after accounting for known activation time between segments. The results showed the presence of TDR in all 3 LV wedges, but there was no significant segmental dispersion of repolarization. Both the measured and the calculated transmural Pseudo-ECGs showed upright T wave that matched the polarity of in vivo ECG. However, the calculated segmental ECG failed to register any T wave. These observations outlined above, clearly demonstrate the prominent role of TDR in the electrocardiographic inscription of the T wave, both in the rabbit and canine LV.Clinical Evidence for Transmural Dispersion of RepolarizationFigure 4 presents a mathematical model in which the ECG was calculated first from a transmural linear array of cells in which repolarization is assumed to be homogeneous and then from a more physiologically-relevant model in which repolarization is heterogeneous.36 In the homogeneous myocardium, the R wave and T wave would be always of opposite polarity and reversal of direction of activation does not have any effect on the QT interval, QRS duration or Tp-e interval. In such a case, the T wave is merely a reflection of the transmural conduction time. In contrast, a transmural repolarization gradient in the heterogeneous myocardium would produce a positive T wave which has the same polarity as the R wave. Download figureDownload PowerPointFigure 4. Mathematical modeling of homogeneous and heterogeneous myocardium. Reproduced with permission from J Am Coll Cardiol. 2005;46:2340–2347.However, clinical observations do not agree with the result of a homogeneous model. Fish et al36 studied the effect of reversing the direction of activation of the left ventricular wall in patients with heart failure (Figure 5). The epicardium of the left ventricular free wall was paced at cycle length of 600 ms through the epicardial electrode of a resynchronization device followed by pacing from the endocardial aspect of the LV free wall by an endovascular catheter at the same cycle length. The effects of epicardial and endocardial pacing on the QT interval and Tp-e interval was measured in lead V6 on body surface ECG. Lead V6 was selected because it was closest to the site of pacing and because it can record the voltage across the transmural axis of the left ventricular wall. A representative recording from such an experiment is shown in Figure 5A. If the assumption that the myocardium is electrically homogeneous is correct, the R and the T wave should always be of opposite polarity and the reversal of direction of activation of the ventricle should not have any effect on QT and Tp-e interval. This is clearly not the case (Figure 5A)36 Reversing the direction of activation of the left ventricular wall by shifting from endocardial to epicardial stimulation caused an increase in the amplitude and width of the T wave, a prolongation of QT interval and a significant increase on Tp-e.33,37 This behavior is also observed in the canine and rabbit left ventricular wedge preparation33,37 (Figure 1) and is predicted by the mathematical model illustrated in Figure 4 to be the result of transmural heterogeneities of repolarization time course. Download figureDownload PowerPointFigure 5. Twelve lead ECGs recorded from human subjects paced from different regions of the ventricular myocardium. A, Changing the ventricular pacing site from endocardium to epicardium increases the QT and Tp-e interval (modified and reproduced with permission from J Am Coll Cardiol. 2005;46:2340–2347). B, Changing the ventricular pacing site from RVA to RVOT has no effect on QT or Tp-e interval.Do the above findings hold true for the apico-basal voltage gradient? In other words, if apico-basal dispersion of repolarization contributes importantly to the genesis of the T wave, then pacing the ventricle from the apex followed by the base should affect the QT and the Tp-e interval in a predictable fashion. To answer this question, we analyzed the ECGs obtained during electrophysiological (EP) study in 5 patients in whom the right ventricle was paced from the apex (RVA) and the outflow tract (RVOT) at a basic cycle length of 600 ms. The QT and Tp-e intervals were calculated during RVA and RVOT pacing. We selected chest lead V2 and limb lead II for evaluation. Chest lead V2 was selected since it measures transmural gradient closest to the site of pacing, and limb lead II was selected because it samples across the apico-basal axis of the heart. As shown in Figure 5B, changing the pacing site from RVA to RVOT did not have any effect on the QT and the Tp-e interval in lead V2 or lead II. The composite data of 5 patients showed that the QT interval remained unchanged (385�16.4 RVA pacing versus 384�13.7 RVOT pacing, p=NS) as did the Tp-e interval (85�3.5 RVA pacing versus 84�3.7 RVOT pacing, p=NS). Changing the pacing site from the RVA to RVOT led to the reversal of the polarity of the T wave in the apico-basal axis in lead II. In contrast, the polarity of the T wave in transmural axis lead V2 remained unchanged.These observations demonstrate the prominent role of TDR over apico-basal dispersion of repolarization in the genesis of T wave. It is important to emphasize that these data do not exclude the presence of apico-basal dispersion of repolarization under some conditions. Several lines of evidence support apico-basal heterogeneity of repolarization. For example, Bauer et al38 have demonstrated that in the canine heart in vivo, the effective refractory period is longer in the epicardial muscle layer of the apex then in the base and on administration of dofetilide apico-basal dispersion of repolarization becomes more pronounced with preferential increase in the refractory period at the apex. Similarly, Janse et al39 reported shortest repolarization times in anterobasal areas and longest repolarization times in posteroapical regions of intact canine LV using unipolar electrograms. Also in enzymatically isolated myocytes from rabbit heart, APD is longer in myocytes isolated from the base as compared with the apex.40Although the apico-basal dispersion of repolarization does exist, such dispersion is much smaller as compared with transmural dispersion. Also, apico-basal dispersion occurs over a much longer distance as compared with transmural dispersion. It is the steepness of the repolarization gradient that is thought to serve as a key factor for arrhythmogenesis and not the total magnitude of dispersion. That is, a small amount of dispersion of repolarization over a long distance will yield a less steep repolarization gradient as in the case of apico-basal repolarization gradient and is less likely to be arrhythmogenic. The transmural dispersion of repolarization is not only more pronounced as compared with apico-basal dispersion, but it also occurs over a much shorter distance resulting in a very steep electric gradient that in our opinion is likely to influence not only the inscription of the T wave but also contribute to arrhythmogenesis.ConclusionsThe presence of an important transmural repolarization gradient in ventricle has been well established in a variety of species, including man. Although apico-basal voltage gradients may contribute, we believe that the transmural voltage gradient plays a predominant role in

Cellular basis for QT dispersion

Repolarization dispersion and life-threatening ventricular tachyarrhythmias in patients with congestive heart failure

The effects of amiodarone on QT dispersion in patients with atrial fibrillation

Cellular Basis for the Normal T Wave and the Electrocardiographic Manifestations of the Long-Qt Syndrome

Transmural dispersion of repolarization and arrhythmogenicity: The brugada syndrome versus the long QT syndrome

Spatiotemporal repolarization dispersion before and after exercise in patients with long QT syndrome type 1 versus controls: probing into the arrhythmia substrate

New insight into repolarization abnormalities in patients with congenital long QT syndrome: the increased transmural dispersion of repolarization

Ventricular Repolarization Dispersion: Friend or Foe

Evaluation of Toxicity for Heart Failure Therapeutics

Evaluation of toxicity for heart failure therapeutics: studying effects on the QT interval.

Mechanisms underlying arrhythmogenesis in long QT syndrome

Clinical significance of QT dispersion after exercise in patients with previous myocardial infarction.

Unique Topographical Distribution Of M Cells Underlies Reentrant Mechanism Of Torsade De Pointes In The Long-Qt Syndrome

T(p-e)/QT Ratio As an Index of Arrhythmogenesis.

Phase 2 Early Afterdepolarization As A Trigger of Polymorphic Ventricular Tachycardia in Acquired Long-Qt Syndrome - Direct Evidence from Intracellular Recordings in the Intact Left Ventricular Wall

L-type Calcium Current Recovery Versus Ventricular Repolarization: Preserved Membrane-Stabilizing Mechanism for Different QT Intervals Across Species.

Is there a significant transmural gradient in repolarization time in the intact heart? Cellular basis of the T wave: a century of controversy.

Mechanisms underlying spontaneous termination of Torsade de Pointes in an experimental model of long QT syndrome

Effect of Epicardial or Biventricular Pacing to Prolong QT Interval and Increase Transmural Dispersion of Repolarization: Does Resynchronization Therapy Pose a Risk for Patients Predisposed to Long QT or Torsade De Pointes?

A study on the relationship between the T-loop morphology and QT dispersion

Is There a Significant Transmural Gradient in Repolarization Time in the Intact Heart?